Willow Biosciences, a leading biotech company focused on sustainable ingredient manufacturing, has announced a collaboration with a major Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable and cost-effective manufacturing process for its largest product sold globally.
The API manufacturer, which holds a significant share of the global market, recognized the need for more sustainable methods with reduced costs and less waste. Willow has been chosen due to its expertise in developing and scaling manufacturing processes for sustainable ingredients. The partnership will focus on optimizing an existing commercial biomanufacturing process for improved performance at scale during the development phase, which is expected to last around six months. Additional milestone payments will be made if performance targets are achieved.
Dr. Chris Savile, President & CEO of Willow Biosciences, expressed excitement at applying Willow’s technology platform towards manufacturing more sustainable APIs for existing large-volume global markets. If successful, these essential ingredients for human health could be made more broadly available while delivering significant value to both partners and shareholders.
This collaboration agreement is Willow’s second new development agreement in just a few weeks of 2024, with a pipeline of potential collaborations in progress.
